Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,738 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Mitral Valve Insufficiency, Coronary Artery Disease
Interventions: MV Repair, MV Replacement, CABG; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more

Conditions: Substance Use Disorders
Interventions: Computerized tasks; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 21 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: VCL-IPM1, VCL-IPT1, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Stony Brook, New York

Conditions: Renal Artery Obstruction
Interventions: Gadobutrol (Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 11 more

Conditions: Alzheimer Disease, Dementia, Hearing Loss, Cognitive Impairment
Interventions: HEARS-NPS device, HEARS-NPS program; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Relapsed/Refractory Follicular Lymphoma
Interventions: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 12
States / cities: Duarte, California • Stanford, California • Tampa, Florida + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, insulin glargine; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 314
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Platelet Aggregation
Interventions: Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®); Drug
Lead sponsor: POZEN; Industry
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions: Trabectedin, Dexamethasone; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: AAV9-hSyn1-miGRIK2; Genetic
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more

Conditions: Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
Interventions: Guardian System; Device
Lead sponsor: Angel Medical Systems; Industry
Eligibility: 21 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more

Conditions: Solid Tumors and Hematologic Malignancy
Interventions: INCB007839; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 4
States / cities: Aurora, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: IDH1-mutant Cholangiocarcinoma
Interventions: Ivosidenib, Nivolumab, Ipilimumab; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Interventions: Azacitidine, Entinostat, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Annapolis, Maryland + 4 more

Conditions: Asthma
Interventions: Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 12 Years and older
Enrollment: 1,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more

Conditions: Alzheimer's Disease in Down Syndrome
Interventions: Not listed
Lead sponsor: LuMind IDSC Foundation; Other
Eligibility: 25 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 11 more

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 63
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 742
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more

Conditions: Stroke
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 24 more

Conditions: Gastroparesis
Interventions: Transcutaneous Electroacupuncture, Sham TEA; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atrial Fibrillation
Interventions: Medtronic Cardiac Ablation System, Class I or III Antiarrhythmic Medications; Procedure · Drug
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 18 more

Search by objective public record fields.

Long Term Follow Up for CTSN Mitral Valve Repair Studies

Cognitive Stimulation in Adolescents

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

Gadobutrol Enhanced MRA of the Renal Arteries

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Allergic Disease Onset Prevention Study

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

AngelMed for Early Recognition and Treatment of STEMI

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Siblings With Ischemic Stroke Study

Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders

Tailored Treatment of Permanent Atrial Fibrillation